clinical trials, non-small-cell lung cancer

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14]

Introduction

Trials reported at ASCO 2009 [1-12] & ASCO 10[13][14] ASCO - American Society of Clinical Oncologists

More general terms

References

  1. ↑ Felip E et al Surgery (S) alone, preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early-stage non-small cell lung cancer (NSCLC): Results of the NATCH multicenter, randomized phase III trial. J Clin Oncol 27:15s, 2009 (suppl; abstr 7500) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32674
  2. ↑ Vincent MD et al Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC). J Clin Oncol 27:15s, 2009 (suppl; abstr 7501) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34914
  3. ↑ Govindan R et al Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol 27:15s, 2009 (suppl; abstr 7505) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34259
  4. ↑ Gore EM et al A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214. J Clin Oncol 27:15s, 2009 (suppl; abstr 7506) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32163
  5. ↑ Belani CP et al Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 27:18s, 2009 (suppl; abstr CRA8000) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33019
  6. ↑ Cappuzzo F et al SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 27:15s, 2009 (suppl; abstr 8001) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32756
  7. ↑ Miller VA et al A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 27:18s, 2009 (suppl; abstr LBA8002) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30819
  8. ↑ Herbst RS et al Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC). J Clin Oncol 27:18s, 2009 (suppl; abstr CRA8003) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31495
  9. ↑ Ramalingam SS et al Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863). J Clin Oncol 27:15s, 2009 (suppl; abstr 8004) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31511
  10. ↑ Groen H et al A randomized placebo-controlled phase III study of docetaxel/ carboplatin with celecoxib in patients (pts) with advanced non-small cell lung cancer (NSCLC): The NVALT-4 study. J Clin Oncol 27:15s, 2009 (suppl; abstr 8005) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33358
  11. ↑ Fukuoka K et al, Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/ paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol 27:15s, 2009 (suppl; abstr 8006^) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30499
  12. ↑ Pirker R et al FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26: 2008 (May 20 suppl; abstr 3) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=55&abstractID=30338
    O'Byrne KJ et al Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. J Clin Oncol 27:15s, 2009 (suppl; abstr 8007) http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=34643
  13. ↑ 13.0 13.1 Davidoff AJ et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010 May 1; 28:2191 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20351329
  14. ↑ 14.0 14.1 ASCO 2010 Report: Lung Cancer GENETIC AND MOLECULAR DRIVERS OF LUNG CANCER Journal Watch: Massachusetts Medical Society http://oncology-hematology.jwatch.org/cgi/content/full/2010/713/5
    Bang Y et al, Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28:18s, 2010 (suppl; abstr 3) http://abstract.asco.org/AbstView_74_50854.html
Retrieved from "https://aaushi.info/w/index.php?title=A322594&oldid=977248"